{"gene":"CIITA","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1994,"finding":"CIITA expression is induced by IFN-γ, and transfection of CIITA is sufficient to activate MHC class II gene expression in class II-negative cells in the absence of IFN-γ, establishing CIITA as a general regulator of both inducible and constitutive MHC class II expression.","method":"Transfection of CIITA into class II-negative cells; IFN-γ stimulation assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional reconstitution by transfection, replicated across multiple labs, foundational finding","pmids":["8016643"],"is_preprint":false},{"year":1994,"finding":"CIITA mediates IFN-γ induction of HLA-DR and invariant chain (Ii) genes; a mutant cell line (G3A) selectively defective in HLA-DR and Ii induction lacks functional CIITA, and a second mutant (G1B) lacking RFX DNA-binding activity also fails to induce DRA and Ii genes by IFN-γ, linking RFX to the IFN-γ response.","method":"Analysis of IFN-γ mutant cell lines; genetic complementation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis using defined mutant cell lines, replicated across multiple independent lines","pmids":["7600294"],"is_preprint":false},{"year":1995,"finding":"Both CIITA and RFX5 are essential regulators of HLA-DMA and HLA-DMB gene expression (constitutive and IFN-γ-inducible), with each cDNA able to correct the respective regulatory mutant defect.","method":"Genetic complementation of regulatory mutant cell lines by cDNA transfection","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional rescue by cDNA transfection in defined mutant lines, replicated for both CIITA and RFX5","pmids":["7495736"],"is_preprint":false},{"year":1997,"finding":"The CIITA gene is controlled by multiple distinct promoters: one directing constitutive expression in dendritic cells, one in B lymphocytes, and one mediating IFN-γ-induced expression, explaining cell-type-specific and inducible MHC class II expression.","method":"Promoter-specific reporter assays; cell-type expression analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — promoter dissection with reporter constructs, replicated across multiple studies","pmids":["9184229"],"is_preprint":false},{"year":1997,"finding":"A dominant-negative CIITA mutant lacking the N-terminal acidic activation domain represses constitutive and IFN-γ-induced MHC class II expression of all three isotypes (HLA-DR, HLA-DQ, HLA-DP), but in a CIITA-deficient B cell line, HLA-DQ expression is not altered, revealing both CIITA-dependent and CIITA-independent class II regulatory pathways.","method":"Dominant-negative CIITA transfection; anti-CIITA monoclonal antibodies; CIITA-deficient cell lines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — dominant-negative approach with multiple isotypes tested, CIITA-deficient cell line control","pmids":["9144488"],"is_preprint":false},{"year":1998,"finding":"RFX5 and RFXAP subunits of the RFX complex are required for both constitutive and CIITA-induced MHC class I and beta2-microglobulin transactivation, and the X1 box within the S-X-Y promoter region is critical for this regulation.","method":"Functional analysis in type III bare lymphocyte syndrome cell lines lacking RFX subunits","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined BLS patient cell lines, replicated for multiple MHC genes","pmids":["9806639"],"is_preprint":false},{"year":1998,"finding":"MHC class II gene silencing in trophoblast cells is caused by inability to induce CIITA expression (not by absence of RFX/X2BP factors or IFN-γ signaling pathway defects); transfection of CIITA into trophoblast cells restores MHC class II expression.","method":"Transfection rescue assay; expression analysis of MHC class II transcription factors in trophoblast cell lines","journal":"American journal of reproductive immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional rescue by CIITA transfection, mechanism localized by exclusion of upstream pathway defects, replicated in PMID 11053628","pmids":["9894561","11053628"],"is_preprint":false},{"year":2000,"finding":"CIITA leucine-rich repeats (LRRs) are required for nuclear localization and in vivo recruitment to the MHC class II promoter (shown by chromatin immunoprecipitation); LRR alanine mutations abolish transactivation capacity and dominant-negative phenotype. CIITA directly interacts with RFX5, RFXANK, NF-YB, and NF-YC through LRR-independent protein-protein interactions. A novel 33 kDa protein interacts with CIITA in an LRR-sensitive manner.","method":"LRR alanine mutagenesis; chromatin immunoprecipitation; co-immunoprecipitation; nuclear localization assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis combined with ChIP and co-IP, multiple orthogonal methods in one study","pmids":["11003667"],"is_preprint":false},{"year":2000,"finding":"Lack of CIITA expression in trophoblast cells is due to hypermethylation of the IFN-γ-inducible promoter IV (PIV) of CIITA; introduction of exogenous CIITA induces MHC class I and II surface expression and antigen presentation capacity.","method":"Bisulfite methylation analysis of CIITA PIV; CIITA transfection rescue; antigen presentation assay","journal":"Human immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — bisulfite sequencing plus functional rescue, two orthogonal methods","pmids":["11053628"],"is_preprint":false},{"year":2001,"finding":"CIITA forms homomeric complexes with itself through a central region including the GTP-binding domain; LXXLL motifs in the GTP-binding domain are essential for self-association. The central region also interacts with the C-terminal LRR and N-terminal acidic domain. CIITA mutants differ in activation function, subcellular localization, and dominant-negative potential.","method":"Co-immunoprecipitation; deletion/point mutagenesis; subcellular localization assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with mutagenesis, single lab, multiple constructs","pmids":["11438649"],"is_preprint":false},{"year":2002,"finding":"IFN-γ induction of CIITA from promoter IV (PIV) requires sequential binding of STAT1 (within 30 min, accompanied by modest histone H3/H4 acetylation) followed by IRF-1 synthesis and binding (>120 min) before CIITA mRNA is detected. Fetal trophoblast-like cells refractory to CIITA induction fail to assemble these factors; bisulfite sequencing shows strong PIV hypermethylation in these cells.","method":"Chromatin immunoprecipitation kinetics; bisulfite sequencing; IFN-γ stimulation time course","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP kinetics combined with bisulfite sequencing, two orthogonal methods, clear temporal resolution","pmids":["12052885"],"is_preprint":false},{"year":2002,"finding":"BRG1, the ATPase subunit of the SWI/SNF chromatin-remodeling complex, is required for IFN-γ induction of CIITA; reconstitution with BRG1 but not an ATPase-deficient mutant (K798R) rescues CIITA induction. BRG1 interacts directly with the endogenous CIITA promoter in an IFN-γ-inducible fashion, and its activity is required for chromatin remodeling at the CIITA locus.","method":"BRG1/hBRM-deficient cell lines; BRG1 reconstitution; chromatin immunoprecipitation; DNase I footprinting; restriction enzyme accessibility","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — functional reconstitution with ATPase-dead mutant control, ChIP, and in vivo chromatin accessibility, multiple orthogonal methods","pmids":["11953317"],"is_preprint":false},{"year":2002,"finding":"CIITA regulates MHC class II transcription initiation by recruiting CDK7 and CDK9 kinases and enhancing CDK7-mediated phosphorylation of RNA Pol II at Ser5, promoting promoter clearance. CIITA is recruited to the DRA enhanceosome after IFN-γ, leading to recruitment of CBP and GCN5 coactivators, histone acetylation, and SWI/SNF recruitment.","method":"Chromatin immunoprecipitation temporal analysis; kinase activity assays; IFN-γ stimulation time course","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP temporal dissection, kinase recruitment assays, multiple orthogonal methods","pmids":["14517250"],"is_preprint":false},{"year":2002,"finding":"The enhanceosome (RFX complex) and CIITA make variable, promoter-dependent contributions to histone acetylation and recruitment of TBP, TFIIB, and RNA Pol II; CIITA is generally required at multiple levels of the activation process across four co-regulated MHC class II genes.","method":"Chromatin immunoprecipitation in RFX-deficient and CIITA-deficient cell lines; analysis of four MHC-II promoters","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP in defined mutant cell lines, multiple genes compared, two loss-of-function backgrounds","pmids":["11889043"],"is_preprint":false},{"year":2003,"finding":"CIITA activates expression of the semaphorin receptor plexin-A1 in dendritic cells; plexin-A1 is required for T cell stimulation by antigen-pulsed DCs but not for peptide binding to MHC. This was identified by cDNA microarray in CIITA-deficient mice and confirmed by shRNA knockdown.","method":"cDNA microarray; shRNA knockdown; T cell stimulation assays; CIITA-deficient and MHC class II-deficient mouse DCs","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — microarray plus shRNA functional validation, CIITA-deficient mouse model, antigen presentation readout","pmids":["12910265"],"is_preprint":false},{"year":2004,"finding":"CIITA contains acetyltransferase (AT) and kinase activities that contribute to MHC class I and II gene transcription; as a general transcription factor, CIITA can functionally replace the TFIID component TAF1 with parallel substrate specificity and regulatory features.","method":"Biochemical activity assays; functional complementation; mutagenesis (reviewed with experimental support cited within)","journal":"Frontiers in immunology (review of experimental findings)","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — review citing in vitro assay data for AT and kinase activities, but primary evidence not directly in this abstract","pmids":["24391648"],"is_preprint":false},{"year":2004,"finding":"Phosphorylation of CIITA at serine residues 286, 288, and 293 downregulates CIITA activity; the nuclear form of CIITA is predominantly phosphorylated whereas cytoplasmic CIITA is predominantly unphosphorylated. Double mutations at these sites increase nuclear CIITA and enhance endogenous MHC class II expression.","method":"Serine-to-alanine mutagenesis; subcellular fractionation; endogenous MHC class II expression assays; phosphorylation site mapping","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis combined with fractionation and functional assay, single lab","pmids":["15210796"],"is_preprint":false},{"year":2004,"finding":"RFX and CIITA bind to novel distal S'-Y' modules located far from known MHC-II gene promoters; these elements function as transcriptional enhancers that are bona fide targets of RFX and CIITA in B cells and IFN-γ-induced cells, inducing broad domains of histone hyperacetylation.","method":"Computational S-Y motif identification; chromatin immunoprecipitation; reporter assays; histone acetylation ChIP","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay combined, computational discovery followed by functional validation","pmids":["15528357"],"is_preprint":false},{"year":2006,"finding":"Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-γ-induced CIITA expression by TLR2-induced MAPK (p38 and ERK) signaling, which causes histone hypoacetylation at CIITA promoter IV and suppression of BRG1 recruitment; this effect is absent in TLR2-deficient macrophages.","method":"Chromatin immunoprecipitation; TLR2 knockout macrophages; MAPK inhibitors (p38, ERK); histone acetylation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP with TLR2-KO genetic control and pharmacological inhibitors, multiple orthogonal approaches","pmids":["16547269"],"is_preprint":false},{"year":2006,"finding":"EZH2, a component of Polycomb repressive complex 2, is present at CIITA promoter IV chromatin in uveal melanoma cells and is associated with trimethylation of H3K27; RNAi-mediated knockdown of EZH2 increases IFN-γ-inducible CIITA transcript levels.","method":"Chromatin immunoprecipitation; RNAi knockdown; histone methylation analysis (3Me-K27-H3)","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus RNAi functional validation, single lab","pmids":["17911618"],"is_preprint":false},{"year":2006,"finding":"M. tuberculosis 19-kDa lipoprotein induces C/EBPβ and C/EBPδ binding to CIITA promoters I and IV, correlating with inhibition of IFN-γ-induced CIITA expression; constitutive expression of C/EBPβ LIP isoform inhibits IFN-γ-induced CIITA expression.","method":"Chromatin immunoprecipitation; oligodeoxynucleotide pulldown; transfection of C/EBPβ LIP; quantitative RT-PCR","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP combined with functional transfection assay, single lab","pmids":["17982082"],"is_preprint":false},{"year":2006,"finding":"ZXDC, a novel zinc finger protein, interacts with the LRR-containing region of CIITA; overexpression of ZXDC super-activates MHC class I and class II promoters by CIITA, and ZXDC silencing reduces CIITA-dependent MHC class II transcription.","method":"Yeast two-hybrid; co-immunoprecipitation; overexpression and shRNA knockdown reporter assays","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus co-IP binding, functional reporter assay, single lab","pmids":["16600381"],"is_preprint":false},{"year":2007,"finding":"ZXDA and ZXDC form a heterocomplex (as well as homodimers) through their zinc finger-containing regions; the ZXDA-ZXDC complex interacts with CIITA and is important for MHC class II gene transcription; ZXDC is present at MHC class II promoters before and after IFN-γ treatment.","method":"Co-immunoprecipitation; knockdown and overexpression assays; chromatin immunoprecipitation","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP binding plus ChIP promoter occupancy, single lab, two orthogonal methods","pmids":["17493635"],"is_preprint":false},{"year":2008,"finding":"BRG1 regulates IFN-γ-mediated CIITA induction through many interdependent distal enhancers rather than through the promoter alone; at uninduced CIITA, BRG1-independent chromatin loops pre-exist, and IFN-γ-induced recruitment of STAT1, IRF1, p300, and histone modifications at distal elements all show BRG1 dependency.","method":"Chromatin immunoprecipitation; chromosome conformation capture (3C); BRG1-deficient cells; histone modification analysis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP combined with 3C chromatin looping and BRG1-deficient functional analysis, multiple orthogonal methods","pmids":["18500344"],"is_preprint":false},{"year":2010,"finding":"PU.1 binds a distal regulatory element (HSS1, 11 kb upstream of CIITA pIII) required for B cell-specific CIITA expression; chromatin conformation capture shows HSS1 physically interacts with CIITA pIII in B cells through PU.1-mediated chromatin looping; PU.1 depletion reduces CIITA expression.","method":"DNase I hypersensitivity; chromatin immunoprecipitation; chromatin conformation capture (3C); shRNA knockdown; bacterial artificial chromosome reporter assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, 3C, functional deletion, and shRNA, multiple orthogonal methods in single lab","pmids":["20363966"],"is_preprint":false},{"year":2011,"finding":"CIITA inhibits HTLV-1 replication by physically interacting with the viral transactivator Tax-1 (via CIITA residues 1-252 and 253-410 interacting with Tax-1 residues 1-108); only CIITA residues 1-252 mediate Tax-1 inhibition. CIITA impairs the physical and functional interaction of Tax-1 with cellular coactivators PCAF, CREB, and ATF1, required for optimal HTLV-1 LTR activation.","method":"Co-immunoprecipitation in vivo; deletion mutagenesis; HTLV-1 LTR luciferase reporter assay; coactivator overexpression rescue","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with deletion mapping, functional reporter assay, rescue experiment, multiple orthogonal methods","pmids":["21813598"],"is_preprint":false},{"year":2011,"finding":"CIITA negatively regulates IL-10 expression in dendritic cells; CIITA-deficient DCs produce increased IL-10 mRNA and protein, while reintroduction of CIITA into CIITA-/- DCs reduces IL-10 production; co-transfection of CIITA with an IL-10 promoter-reporter decreases IL-10 promoter activity.","method":"CIITA-/- mouse DCs; CIITA reconstitution; IL-10 promoter-reporter assay; LPS/CpG stimulation","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse plus reconstitution plus reporter assay, single lab","pmids":["15661876"],"is_preprint":false},{"year":2011,"finding":"PRDM1/Blimp-1 silences CIITA expression in maturing dendritic cells by recruiting co-repressors G9a and HDAC2 to CIITA promoter I, causing loss of histone acetylation and acquisition of H3K9 dimethylation and HP1γ; IRF8/PU.1 heterodimer binding is required for CIITApI activation in immature DCs and is blocked by PRDM1.","method":"In vivo genomic footprinting; chromatin immunoprecipitation; IRF8-null mouse DCs; PRDM1 reporter assays; DC maturation model","journal":"Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP combined with IRF8-null mice, in vivo footprinting, and functional reporter assays, multiple orthogonal methods","pmids":["21216962"],"is_preprint":false},{"year":2011,"finding":"SIRT1 deacetylase interacts with and deacetylates CIITA; SIRT1 activation augments MHC II transcription by protecting CIITA from proteasomal degradation and promoting nuclear accumulation and promoter binding; SIRT1 depletion increases CIITA acetylation and attenuates its activity. Stress stimuli (hypobaric hypoxia, oxLDL) induce CIITA acetylation and suppress its activity by inhibiting SIRT1.","method":"Co-immunoprecipitation; deacetylation assay; proteasome inhibition; nuclear fractionation; chromatin immunoprecipitation; SIRT1 activator/inhibitor treatment","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP, proteasome assay, ChIP, and stress stimuli models, multiple orthogonal methods in single lab","pmids":["21890893"],"is_preprint":false},{"year":2015,"finding":"Genome-wide ChIP-seq reveals CIITA binds 480 sites in B cells, predominantly at active promoters and enhancers containing accessible chromatin; CIITA binding correlates with increased H3K27 acetylation at non-regulated loci, suggesting a chromatin-poising function; computational modeling of XY box motifs defines sequence constraints distinguishing CIITA-mediated regulation from mere binding.","method":"ChIP-seq; CIITA-null cell lines (including CRISPR/Cas9-generated); histone modification analysis; computational motif modeling","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — genome-wide ChIP-seq with CRISPR KO validation, multiple orthogonal methods in single lab","pmids":["25753668"],"is_preprint":false},{"year":2016,"finding":"CIITA inhibits HIV-1 replication in myeloid (U937) cells by targeting the viral transactivator Tat to inhibit Tat-dependent HIV-1 LTR transactivation; this is independent of TRIM22 expression. Overexpression of CIITA in permissive U937 Plus cells restores suppression of Tat transactivation.","method":"Stable CIITA overexpression; HIV-1 LTR luciferase reporter assay; reverse transcriptase activity measurement; flow cytometry; western blot","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assay and viral replication measurement with gain-of-function, single lab","pmids":["27089879"],"is_preprint":false},{"year":2017,"finding":"PRMT1 methylates CIITA and promotes CIITA proteasomal degradation, thereby repressing MHC class II transcription in macrophages; IFN-γ treatment downregulates PRMT1 expression and attenuates PRMT1 binding to the MHC II promoter; PRMT1 overexpression represses while PRMT1 depletion enhances MHC II transactivation.","method":"Co-immunoprecipitation; in vitro methylation assay; chromatin immunoprecipitation; PRMT1 overexpression and knockdown; MHC II promoter reporter assay","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus in vitro methylation, ChIP, and gain/loss-of-function, single lab","pmids":["28094290"],"is_preprint":false},{"year":2016,"finding":"PRMT5 interacts with CIITA and is recruited by CIITA to the MHC II promoter; PRMT5 potentiates IFN-γ-induced MHC II transcription in an enzyme activity-dependent manner by symmetrically dimethylating H3R2 (H3R2Me2s) and mediating synergy between PRMT5 and ASH2/WDR5; PRMT5 silencing or inhibition suppresses MHC II transactivation.","method":"Co-immunoprecipitation; chromatin immunoprecipitation; PRMT5 overexpression and knockdown; enzyme activity inhibitor (MTA); histone methylation assay","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ChIP, and gain/loss-of-function with enzyme-dead validation, single lab","pmids":["26972221"],"is_preprint":false},{"year":2018,"finding":"NFAT5 is required for expression of CIITA and MHC class II in macrophages (but not dendritic cells); NFAT5-deficient macrophages show defective CD4+ T cell activation and impaired graft rejection in vivo. NFAT5 regulates a distal upstream enhancer of Ciita that physically interacts with the Ciita myeloid promoter I and exhibits NFAT5-dependent H3K27 acetylation.","method":"NFAT5-deficient macrophages; CHIP-seq (ultrasequencing of NFAT5-immunoprecipitated chromatin); H3K27 acetylation ChIP; in vivo graft rejection model; CD4+ T cell activation assay","journal":"Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq combined with KO mouse functional assays (T cell activation, graft rejection), multiple orthogonal methods","pmids":["30327417"],"is_preprint":false},{"year":2019,"finding":"CIITA interacts with and recruits the histone H3K9 trimethyltransferase SUV39H1 to the eNOS promoter, resulting in H3K9Me3 enrichment and transcriptional repression of eNOS in endothelial cells in response to IFN-γ; CIITA depletion normalizes H3K4Me3 and H3K9Me3 at the eNOS promoter; SUV39H1 silencing abrogates IFN-γ-induced eNOS repression.","method":"Chromatin immunoprecipitation; co-immunoprecipitation; CIITA overexpression and knockdown; SUV39H1 knockdown; histone methylation analysis (H3K9Me3, H3K4Me3)","journal":"Biochimica et biophysica acta. Gene regulatory mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP combined with co-IP and gain/loss-of-function, single lab","pmids":["30716531"],"is_preprint":false},{"year":2020,"finding":"CIITA induces resistance to Ebola virus by activating expression of the p41 isoform of the invariant chain CD74, which inhibits viral entry by blocking cathepsin-mediated processing of the Ebola glycoprotein; CD74 p41 also blocks the endosomal entry pathway of SARS-CoV-2 and other coronaviruses.","method":"Transposon-mediated gene-activation screen; CD74 p41 expression; viral entry assays; cathepsin activity assays; CIITA and CD74 gain-of-function","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional screen followed by mechanistic validation of CD74 p41 as effector, viral entry and cathepsin assays, multiple viruses tested","pmids":["32855215"],"is_preprint":false},{"year":2023,"finding":"FBXO11, a member of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex, is a binding partner and E3 ligase for CIITA; FBXO11 promotes ubiquitin-dependent proteasomal degradation of CIITA and is the major regulator of CIITA half-life. FBXO11 expression reduces MHC class II promoter activity, transcript levels, and surface expression through CIITA downregulation; FBXO11-deficient cells display increased MHC II and related genes.","method":"Unbiased proteomics for CIITA-binding proteins; cycloheximide chase assay; ubiquitination assay; MHC II promoter reporter; flow cytometry; FBXO11-deficient human and mouse cells","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — unbiased proteomics plus degradation assay, ubiquitination assay, and KO cell functional validation, multiple orthogonal methods","pmids":["37279268"],"is_preprint":false},{"year":2022,"finding":"In osteocytes, CIITA upregulates secretion of osteolytic cytokines (RANKL/TNFSF11 and sclerostin/SOST) through histone H3K14 acetylation at their promoters, promoting osteoclastogenesis and decreasing osteoblastogenesis; myeloma cell-secreted 2-deoxy-D-ribose upregulates CIITA expression in osteocytes through STAT1/IRF1 signaling.","method":"Chromatin immunoprecipitation (H3K14 acetylation); CIITA overexpression in osteocytes; osteoclastogenesis assays; STAT1/IRF1 pathway analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus gain-of-function and pathway inhibition, single lab","pmids":["35760800"],"is_preprint":false},{"year":2006,"finding":"CREB and phospho-CREB interact with CIITA and with the RFX5 subunit of the RFX complex through the C-terminal portion of CREB; phospho-CREB is found at the HLA-DRA promoter by ChIP; phosphorylation of CREB enhances but is not required for transcription from MHC-II promoter reporters.","method":"Co-immunoprecipitation with CREB mutants; reporter assays; chromatin immunoprecipitation","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with mutant mapping, ChIP, and reporter assay, single lab","pmids":["16730065"],"is_preprint":false}],"current_model":"CIITA is a master transcriptional coactivator that does not bind DNA directly but is recruited to MHC class II (and related) promoters through protein–protein interactions with the RFX complex (RFX5, RFXANK), NF-Y, and CREB; once at the promoter, CIITA coordinates chromatin remodeling (via BRG1/SWI/SNF), histone acetylation (recruiting CBP/GCN5/PCAF and possessing intrinsic acetyltransferase activity), and transcription initiation (via CDK7/CDK9-mediated Ser5 phosphorylation of RNA Pol II). Its nuclear localization depends on intact leucine-rich repeats (LRRs), and its activity is tightly regulated by post-translational modifications including phosphorylation (at Ser286/288/293 to downregulate activity), acetylation (reversed by SIRT1 to promote stability and nuclear accumulation), methylation by PRMT1 (promoting proteasomal degradation), and ubiquitin-dependent proteasomal degradation driven by the E3 ligase FBXO11. CIITA expression is itself governed by multiple cell-type-specific promoters controlled by STAT1, IRF-1, PU.1/IRF8, NFAT5, and epigenetic mechanisms including DNA methylation and histone modifications; it also functions as a viral restriction factor by sequestering Tax-1 (HTLV-1) and Tat (HIV-1) transactivators and by inducing CD74 p41 to block cathepsin-mediated entry of Ebola virus and SARS-CoV-2."},"narrative":{"mechanistic_narrative":"CIITA is the master transcriptional coactivator of the MHC class II response, sufficient to switch on MHC class II genes in class II-negative cells and acting as the general regulator of both constitutive and IFN-γ-inducible class II expression [PMID:8016643, PMID:7600294]. It does not bind DNA itself but is recruited to the conserved S-X-Y promoter module through the RFX complex (RFX5, RFXANK), NF-Y (NF-YB/NF-YC), and CREB, with these LRR-independent protein-protein contacts positioning CIITA at the enhanceosome while its leucine-rich repeats govern nuclear localization and stable promoter occupancy [PMID:11003667, PMID:9806639, PMID:16730065]. Once recruited, CIITA orchestrates a coordinated activation program: it directs SWI/SNF-dependent chromatin remodeling via the BRG1 ATPase, recruits the CBP/GCN5 acetyltransferases to drive histone acetylation, and promotes transcription initiation by recruiting CDK7/CDK9 and enhancing Ser5 phosphorylation of RNA Pol II for promoter clearance [PMID:11953317, PMID:14517250, PMID:11889043]. Genome-wide it binds hundreds of active promoters and enhancers, including distal S'-Y' modules, where it poises chromatin through H3K27 acetylation [PMID:25753668, PMID:15528357]. CIITA expression is itself the principal control point, set by multiple cell-type-specific promoters whose use depends on STAT1/IRF-1 (IFN-γ-inducible promoter IV), PU.1/IRF8 (B-cell and DC promoters), and NFAT5 (myeloid), and is silenced by promoter hypermethylation, EZH2/H3K27me3, and PRDM1-recruited G9a/HDAC2 repression [PMID:9184229, PMID:12052885, PMID:20363966, PMID:30327417, PMID:11053628, PMID:17911618, PMID:21216962]. CIITA activity and stability are tuned by post-translational modifications—inhibitory phosphorylation at Ser286/288/293, SIRT1-reversible acetylation controlling nuclear accumulation, PRMT1 methylation driving degradation, and FBXO11-mediated ubiquitin-dependent proteasomal turnover as the major determinant of its half-life [PMID:15210796, PMID:21890893, PMID:28094290, PMID:37279268]. Beyond antigen presentation CIITA acts as a viral restriction factor, sequestering the HTLV-1 Tax-1 and HIV-1 Tat transactivators and inducing the CD74 p41 isoform to block cathepsin-dependent entry of Ebola virus and SARS-CoV-2, and it can also act as a context-dependent repressor, recruiting SUV39H1 to silence eNOS and suppressing IL-10 [PMID:21813598, PMID:27089879, PMID:32855215, PMID:30716531, PMID:15661876].","teleology":[{"year":1994,"claim":"Established that a single factor controls the MHC class II regulon, answering whether class II induction by IFN-γ required a dedicated master regulator.","evidence":"Transfection of CIITA into class II-negative cells and IFN-γ stimulation, plus genetic complementation of IFN-γ-defective mutant cell lines","pmids":["8016643","7600294"],"confidence":"High","gaps":["Did not define how CIITA reaches the promoter","Mechanism of transactivation unresolved"]},{"year":1995,"claim":"Defined the partition of labor between CIITA and the RFX complex, showing both are essential and act on overlapping sets of MHC genes including HLA-DM.","evidence":"cDNA complementation of distinct regulatory mutant cell lines for HLA-DMA/DMB","pmids":["7495736"],"confidence":"High","gaps":["Physical relationship between CIITA and RFX not yet shown","Promoter element requirements undefined"]},{"year":1997,"claim":"Explained cell-type-specific and inducible class II expression by mapping CIITA to multiple distinct promoters and identifying CIITA-independent regulatory routes.","evidence":"Promoter-specific reporter assays, cell-type expression analysis, and dominant-negative CIITA lacking the activation domain","pmids":["9184229","9144488"],"confidence":"High","gaps":["Upstream transcription factors at each promoter not identified","Basis of CIITA-independent HLA-DQ regulation unknown"]},{"year":1998,"claim":"Showed CIITA also governs MHC class I and beta2-microglobulin via the RFX/S-X-Y machinery, and that physiological class II silencing in trophoblast reflects failure to induce CIITA itself.","evidence":"Bare lymphocyte syndrome cell lines lacking RFX5/RFXAP; transfection rescue and exclusion of upstream defects in trophoblast","pmids":["9806639","9894561","11053628"],"confidence":"High","gaps":["Cause of CIITA promoter silencing in trophoblast not yet defined","Direct CIITA-RFX contact still inferred"]},{"year":2000,"claim":"Mapped the structural basis of CIITA recruitment and assembly, distinguishing LRR-dependent localization/promoter binding from LRR-independent partner contacts and self-association.","evidence":"LRR alanine mutagenesis, ChIP, co-IP with RFX5/RFXANK/NF-YB/NF-YC, nuclear localization assays, and homodimerization mapping; bisulfite analysis of promoter IV in trophoblast","pmids":["11003667","11438649","11053628"],"confidence":"High","gaps":["Identity of the LRR-sensitive 33 kDa partner unresolved","Functional role of GTP-binding domain self-association unclear"]},{"year":2002,"claim":"Resolved both how CIITA is induced and what it does at target promoters, defining the STAT1→IRF-1 kinetic cascade, BRG1/SWI/SNF chromatin remodeling, and CDK7/CDK9-mediated Pol II Ser5 phosphorylation.","evidence":"ChIP kinetics with bisulfite sequencing, BRG1 reconstitution with ATPase-dead control, kinase recruitment assays, and ChIP across four MHC-II promoters","pmids":["12052885","11953317","14517250","11889043"],"confidence":"High","gaps":["Whether CIITA enzymatic activities are intrinsic vs recruited not settled","Quantitative contributions of each step vary by promoter"]},{"year":2003,"claim":"Extended the CIITA regulon beyond MHC to identify functional non-MHC targets relevant to antigen presentation, such as plexin-A1 in dendritic cells.","evidence":"cDNA microarray in CIITA-deficient mouse DCs with shRNA validation and T-cell stimulation assays","pmids":["12910265"],"confidence":"High","gaps":["Promoter elements mediating CIITA control of plexin-A1 undefined","Breadth of non-MHC targets not yet genome-wide"]},{"year":2004,"claim":"Proposed CIITA as a general transcription factor with intrinsic acetyltransferase/kinase activities and TAF1-like function, and uncovered distal S'-Y' enhancers and inhibitory phosphorylation as activity controls.","evidence":"Biochemical activity assays and TAF1 complementation (reviewed); ChIP/reporter of distal enhancers; Ser286/288/293 mutagenesis with fractionation","pmids":["24391648","15528357","15210796"],"confidence":"Medium","gaps":["Primary structural/biochemical evidence for intrinsic enzymatic activities limited","Kinase responsible for inhibitory Ser phosphorylation not identified"]},{"year":2006,"claim":"Defined transcriptional repression of CIITA by pathogens and the cofactor environment, linking TLR2/MAPK signaling, C/EBP, EZH2, ZXDC/ZXDA, and CREB to CIITA promoter control and coactivation.","evidence":"ChIP with TLR2-KO macrophages and MAPK inhibitors; C/EBPβ LIP transfection; EZH2 RNAi; yeast two-hybrid and co-IP for ZXDC/ZXDA; CREB mutant co-IP and ChIP","pmids":["16547269","17982082","17911618","16600381","16730065"],"confidence":"Medium","gaps":["Mechanistic interplay among these repressors not integrated","Direct vs indirect cofactor effects on CIITA not all resolved"]},{"year":2008,"claim":"Revealed that CIITA induction is controlled through long-range chromatin architecture, with BRG1-dependent distal enhancers and pre-existing chromatin loops.","evidence":"ChIP combined with chromosome conformation capture (3C) in BRG1-deficient cells with histone modification analysis","pmids":["18500344"],"confidence":"High","gaps":["Architectural proteins establishing the loops not identified","Mechanism of BRG1-independent pre-existing loops unknown"]},{"year":2011,"claim":"Identified lineage- and maturation-specific control of CIITA and the post-translational acetylation switch, and uncovered CIITA's antiviral and immunoregulatory moonlighting functions.","evidence":"PU.1/HSS1 3C and shRNA; PRDM1/G9a/HDAC2 footprinting in IRF8-null DCs; SIRT1 deacetylation/proteasome/ChIP assays; Tax-1 co-IP and LTR reporter; CIITA-/- DC IL-10 reporter","pmids":["20363966","21216962","21890893","21813598","15661876"],"confidence":"High","gaps":["How DC maturation triggers PRDM1 recruitment unresolved","Specificity determinants of CIITA acetylation sites not mapped"]},{"year":2017,"claim":"Established arginine methylation as a bidirectional regulator of CIITA, with PRMT1 driving degradation and PRMT5 potentiating transcription, and defined the genome-wide CIITA binding landscape.","evidence":"Co-IP and in vitro methylation with PRMT1/PRMT5 gain/loss-of-function and ChIP; genome-wide ChIP-seq with CRISPR-null validation","pmids":["28094290","26972221","25753668"],"confidence":"Medium","gaps":["Methylated residues on CIITA not precisely mapped","Distinction between CIITA binding and functional regulation incompletely defined"]},{"year":2020,"claim":"Defined NFAT5-dependent myeloid CIITA control, the FBXO11 E3 ligase as the major determinant of CIITA half-life, and effector mechanisms of CIITA in viral restriction, vascular gene silencing, and bone remodeling.","evidence":"NFAT5-KO macrophage ChIP-seq with graft rejection; FBXO11 proteomics, ubiquitination and cycloheximide chase; CD74 p41 viral entry/cathepsin assays; SUV39H1 co-IP/ChIP at eNOS; H3K14ac ChIP in osteocytes; HIV-1 Tat LTR reporter","pmids":["30327417","37279268","32855215","30716531","35760800","27089879"],"confidence":"High","gaps":["Signals selecting CIITA for FBXO11 ubiquitination not defined","Mechanism by which CIITA switches between activator and SUV39H1-recruiting repressor unknown"]},{"year":null,"claim":"How the diverse post-translational modifications (phosphorylation, acetylation, arginine methylation, ubiquitination) are integrated to set CIITA activity, stability, and its choice between activator and repressor roles remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking PTM crosstalk to functional output","Structural basis of CIITA assembly at the enhanceosome not determined","Determinants of activator vs repressor mode unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,7,29]},{"term_id":"GO:0140223","term_label":"general transcription initiation factor activity","supporting_discovery_ids":[15]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[12,15]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[25,30,35]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,14,35]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,11,12,13]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[11,23,27,34]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[25,30,35]}],"complexes":[],"partners":["RFX5","RFXANK","NFYB","NFYC","CREB","ZXDC","SIRT1","FBXO11"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P33076","full_name":"MHC class II transactivator","aliases":[],"length_aa":1130,"mass_kda":123.4,"function":"Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter (PubMed:16600381, PubMed:17493635, PubMed:7749984, PubMed:8402893, PubMed:40608405). Does not bind DNA (PubMed:16600381, PubMed:17493635, PubMed:7749984, PubMed:8402893). May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984, (PubMed:16600381, PubMed:17493635). Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter (PubMed:16600381, PubMed:17493635, PubMed:7749984, PubMed:8402893). Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Activates CD74 transcription (PubMed:32855215). Exhibits intrinsic GTP-stimulated acetyltransferase activity (PubMed:11172716). Exhibits serine/threonine protein kinase activity: can phosphorylate the TFIID component TAF7, the RAP74 subunit of the general transcription factor TFIIF, histone H2B at 'Ser-37' and other histones (in vitro) (PubMed:24036077). Has antiviral activity against Ebola virus and coronaviruses, including SARS-CoV-2 (PubMed:32855215). Induces resistance by up-regulation of the p41 isoform of CD74, which blocks cathepsin-mediated cleavage of viral glycoproteins, thereby preventing viral fusion (PubMed:32855215) Exhibits dominant-negative suppression of MHC class II gene expression","subcellular_location":"Nucleus; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/P33076/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CIITA","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CIITA","total_profiled":1310},"omim":[{"mim_id":"620815","title":"MHC CLASS II DEFICIENCY 2; MHC2D2","url":"https://www.omim.org/entry/620815"},{"mim_id":"615746","title":"ZXD FAMILY ZINC FINGER PROTEIN C; ZXDC","url":"https://www.omim.org/entry/615746"},{"mim_id":"615648","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 3; NLRC3","url":"https://www.omim.org/entry/615648"},{"mim_id":"613591","title":"BUTYROPHILIN, SUBFAMILY 2, MEMBER A2; BTN2A2","url":"https://www.omim.org/entry/613591"},{"mim_id":"613537","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 5; NLRC5","url":"https://www.omim.org/entry/613537"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":50.4}],"url":"https://www.proteinatlas.org/search/CIITA"},"hgnc":{"alias_symbol":["C2TA","NLRA"],"prev_symbol":["MHC2TA"]},"alphafold":{"accession":"P33076","domains":[{"cath_id":"3.40.50.300","chopping":"337-569","consensus_level":"high","plddt":74.4797,"start":337,"end":569},{"cath_id":"3.80.10.10","chopping":"916-1129","consensus_level":"medium","plddt":90.7375,"start":916,"end":1129},{"cath_id":"1.10.8","chopping":"572-634","consensus_level":"medium","plddt":89.3333,"start":572,"end":634}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P33076","model_url":"https://alphafold.ebi.ac.uk/files/AF-P33076-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P33076-F1-predicted_aligned_error_v6.png","plddt_mean":68.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CIITA","jax_strain_url":"https://www.jax.org/strain/search?query=CIITA"},"sequence":{"accession":"P33076","fasta_url":"https://rest.uniprot.org/uniprotkb/P33076.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P33076/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P33076"}},"corpus_meta":[{"pmid":"8016643","id":"PMC_8016643","title":"Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8016643","citation_count":763,"is_preprint":false},{"pmid":"21368758","id":"PMC_21368758","title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21368758","citation_count":479,"is_preprint":false},{"pmid":"9184229","id":"PMC_9184229","title":"Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9184229","citation_count":395,"is_preprint":false},{"pmid":"15821736","id":"PMC_15821736","title":"MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction.","date":"2005","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15821736","citation_count":256,"is_preprint":false},{"pmid":"15162420","id":"PMC_15162420","title":"Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15162420","citation_count":235,"is_preprint":false},{"pmid":"16547269","id":"PMC_16547269","title":"Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-gamma-induced chromatin remodeling of MHC2TA by TLR2 and MAPK signaling.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16547269","citation_count":172,"is_preprint":false},{"pmid":"16870508","id":"PMC_16870508","title":"Epigenetic regulation of MHC-II and CIITA genes.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16870508","citation_count":164,"is_preprint":false},{"pmid":"7600294","id":"PMC_7600294","title":"Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction.","date":"1994","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7600294","citation_count":128,"is_preprint":false},{"pmid":"12910265","id":"PMC_12910265","title":"CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions.","date":"2003","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12910265","citation_count":111,"is_preprint":false},{"pmid":"24391648","id":"PMC_24391648","title":"CIITA and Its Dual Roles in MHC Gene Transcription.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24391648","citation_count":100,"is_preprint":false},{"pmid":"32855215","id":"PMC_32855215","title":"MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32855215","citation_count":99,"is_preprint":false},{"pmid":"12052885","id":"PMC_12052885","title":"Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12052885","citation_count":98,"is_preprint":false},{"pmid":"26549456","id":"PMC_26549456","title":"Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26549456","citation_count":98,"is_preprint":false},{"pmid":"18593762","id":"PMC_18593762","title":"Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18593762","citation_count":94,"is_preprint":false},{"pmid":"9806639","id":"PMC_9806639","title":"The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes.","date":"1998","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9806639","citation_count":92,"is_preprint":false},{"pmid":"7495736","id":"PMC_7495736","title":"The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes.","date":"1995","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7495736","citation_count":91,"is_preprint":false},{"pmid":"11003667","id":"PMC_11003667","title":"CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11003667","citation_count":91,"is_preprint":false},{"pmid":"11953317","id":"PMC_11953317","title":"Interferon-gamma-induced chromatin remodeling at the CIITA locus is BRG1 dependent.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11953317","citation_count":90,"is_preprint":false},{"pmid":"18500344","id":"PMC_18500344","title":"The chromatin-remodeling enzyme BRG1 coordinates CIITA induction through many interdependent distal enhancers.","date":"2008","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18500344","citation_count":88,"is_preprint":false},{"pmid":"31417570","id":"PMC_31417570","title":"CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31417570","citation_count":85,"is_preprint":false},{"pmid":"15653312","id":"PMC_15653312","title":"Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes.","date":"2005","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15653312","citation_count":82,"is_preprint":false},{"pmid":"21464590","id":"PMC_21464590","title":"Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.","date":"2011","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21464590","citation_count":77,"is_preprint":false},{"pmid":"23789844","id":"PMC_23789844","title":"Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.","date":"2013","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23789844","citation_count":76,"is_preprint":false},{"pmid":"9885917","id":"PMC_9885917","title":"Mice lacking the transcription factor CIITA--a second look.","date":"1998","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9885917","citation_count":75,"is_preprint":false},{"pmid":"14517250","id":"PMC_14517250","title":"CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/14517250","citation_count":72,"is_preprint":false},{"pmid":"33499042","id":"PMC_33499042","title":"The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33499042","citation_count":68,"is_preprint":false},{"pmid":"11053628","id":"PMC_11053628","title":"Lack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-gamma inducible promoter (PIV) of CIITA.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11053628","citation_count":60,"is_preprint":false},{"pmid":"17982082","id":"PMC_17982082","title":"CCAAT/enhancer-binding protein beta and delta binding to CIITA promoters is associated with the inhibition of CIITA expression in response to Mycobacterium tuberculosis 19-kDa lipoprotein.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17982082","citation_count":55,"is_preprint":false},{"pmid":"17911618","id":"PMC_17911618","title":"A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17911618","citation_count":53,"is_preprint":false},{"pmid":"30327417","id":"PMC_30327417","title":"Macrophage-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30327417","citation_count":53,"is_preprint":false},{"pmid":"15528357","id":"PMC_15528357","title":"Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15528357","citation_count":51,"is_preprint":false},{"pmid":"21216962","id":"PMC_21216962","title":"Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21216962","citation_count":50,"is_preprint":false},{"pmid":"9144488","id":"PMC_9144488","title":"CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9144488","citation_count":49,"is_preprint":false},{"pmid":"11746775","id":"PMC_11746775","title":"Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.","date":"2001","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/11746775","citation_count":48,"is_preprint":false},{"pmid":"11889043","id":"PMC_11889043","title":"Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11889043","citation_count":47,"is_preprint":false},{"pmid":"30716531","id":"PMC_30716531","title":"Class II transactivator (CIITA) mediates IFN-γ induced eNOS repression by enlisting SUV39H1.","date":"2019","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30716531","citation_count":45,"is_preprint":false},{"pmid":"23776173","id":"PMC_23776173","title":"Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23776173","citation_count":45,"is_preprint":false},{"pmid":"10505975","id":"PMC_10505975","title":"Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha.","date":"1999","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/10505975","citation_count":44,"is_preprint":false},{"pmid":"17012290","id":"PMC_17012290","title":"Role of the MHC2TA gene in autoimmune diseases.","date":"2006","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17012290","citation_count":43,"is_preprint":false},{"pmid":"12218128","id":"PMC_12218128","title":"Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12218128","citation_count":43,"is_preprint":false},{"pmid":"15661876","id":"PMC_15661876","title":"Enhanced production of IL-10 by dendritic cells deficient in CIITA.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15661876","citation_count":43,"is_preprint":false},{"pmid":"20211854","id":"PMC_20211854","title":"CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20211854","citation_count":42,"is_preprint":false},{"pmid":"12391222","id":"PMC_12391222","title":"Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: identification of a novel regulatory region in the 5'-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12391222","citation_count":41,"is_preprint":false},{"pmid":"16343978","id":"PMC_16343978","title":"Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16343978","citation_count":40,"is_preprint":false},{"pmid":"9882346","id":"PMC_9882346","title":"Human parainfluenza virus type 3 up-regulates major histocompatibility complex class I and II expression on respiratory epithelial cells: involvement of a STAT1- and CIITA-independent pathway.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9882346","citation_count":39,"is_preprint":false},{"pmid":"9894561","id":"PMC_9894561","title":"MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression.","date":"1998","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/9894561","citation_count":38,"is_preprint":false},{"pmid":"17300840","id":"PMC_17300840","title":"MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17300840","citation_count":38,"is_preprint":false},{"pmid":"32732833","id":"PMC_32732833","title":"Generation of GGTA1-/-β2M-/-CIITA-/- Pigs Using CRISPR/Cas9 Technology to Alleviate Xenogeneic Immune Reactions.","date":"2020","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/32732833","citation_count":37,"is_preprint":false},{"pmid":"11438649","id":"PMC_11438649","title":"Self-association of CIITA and its transactivation potential.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11438649","citation_count":37,"is_preprint":false},{"pmid":"31969878","id":"PMC_31969878","title":"Helicobacter pylori Dampens HLA-II Expression on Macrophages via the Up-Regulation of miRNAs Targeting CIITA.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31969878","citation_count":34,"is_preprint":false},{"pmid":"19081173","id":"PMC_19081173","title":"Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19081173","citation_count":34,"is_preprint":false},{"pmid":"21813598","id":"PMC_21813598","title":"Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.","date":"2011","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/21813598","citation_count":34,"is_preprint":false},{"pmid":"15950283","id":"PMC_15950283","title":"Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma.","date":"2005","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15950283","citation_count":32,"is_preprint":false},{"pmid":"18453624","id":"PMC_18453624","title":"Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18453624","citation_count":31,"is_preprint":false},{"pmid":"21890893","id":"PMC_21890893","title":"SIRT1 links CIITA deacetylation to MHC II activation.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21890893","citation_count":30,"is_preprint":false},{"pmid":"16849401","id":"PMC_16849401","title":"MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16849401","citation_count":29,"is_preprint":false},{"pmid":"25753668","id":"PMC_25753668","title":"Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25753668","citation_count":29,"is_preprint":false},{"pmid":"28094290","id":"PMC_28094290","title":"Protein arginine methyltransferase 1 (PRMT1) represses MHC II transcription in macrophages by methylating CIITA.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28094290","citation_count":29,"is_preprint":false},{"pmid":"17678724","id":"PMC_17678724","title":"Environment-gene interaction in multiple sclerosis: human herpesvirus 6 and MHC2TA.","date":"2007","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17678724","citation_count":28,"is_preprint":false},{"pmid":"33592498","id":"PMC_33592498","title":"CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.","date":"2021","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/33592498","citation_count":28,"is_preprint":false},{"pmid":"16951349","id":"PMC_16951349","title":"Epigenetic regulation during B cell differentiation controls CIITA promoter accessibility.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16951349","citation_count":28,"is_preprint":false},{"pmid":"20363966","id":"PMC_20363966","title":"PU.1 binds to a distal regulatory element that is necessary for B cell-specific expression of CIITA.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20363966","citation_count":28,"is_preprint":false},{"pmid":"37467968","id":"PMC_37467968","title":"The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.","date":"2023","source":"Biomedical journal","url":"https://pubmed.ncbi.nlm.nih.gov/37467968","citation_count":26,"is_preprint":false},{"pmid":"30723578","id":"PMC_30723578","title":"CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30723578","citation_count":26,"is_preprint":false},{"pmid":"16879803","id":"PMC_16879803","title":"Epigenetic silencing of MHC2TA transcription in cancer.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16879803","citation_count":25,"is_preprint":false},{"pmid":"17875550","id":"PMC_17875550","title":"The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association.","date":"2007","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17875550","citation_count":25,"is_preprint":false},{"pmid":"15210796","id":"PMC_15210796","title":"Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15210796","citation_count":25,"is_preprint":false},{"pmid":"27089879","id":"PMC_27089879","title":"The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.","date":"2016","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27089879","citation_count":25,"is_preprint":false},{"pmid":"19395374","id":"PMC_19395374","title":"Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.","date":"2009","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19395374","citation_count":25,"is_preprint":false},{"pmid":"19659749","id":"PMC_19659749","title":"MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients.","date":"2009","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19659749","citation_count":24,"is_preprint":false},{"pmid":"32188757","id":"PMC_32188757","title":"In Primitive Zebrafish, MHC Class II Expression Is Regulated by IFN-γ, IRF1, and Two Forms of CIITA.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32188757","citation_count":24,"is_preprint":false},{"pmid":"16600381","id":"PMC_16600381","title":"ZXDC, a novel zinc finger protein that binds CIITA and activates MHC gene transcription.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16600381","citation_count":24,"is_preprint":false},{"pmid":"15326139","id":"PMC_15326139","title":"Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.","date":"2004","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/15326139","citation_count":23,"is_preprint":false},{"pmid":"37279268","id":"PMC_37279268","title":"FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37279268","citation_count":23,"is_preprint":false},{"pmid":"10845913","id":"PMC_10845913","title":"Synergistic induction of HLA class I expression by RelA and CIITA.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10845913","citation_count":23,"is_preprint":false},{"pmid":"17493635","id":"PMC_17493635","title":"The zinc finger proteins ZXDA and ZXDC form a complex that binds CIITA and regulates MHC II gene transcription.","date":"2007","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17493635","citation_count":23,"is_preprint":false},{"pmid":"21614020","id":"PMC_21614020","title":"The rs4774 CIITA missense variant is associated with risk of systemic lupus erythematosus.","date":"2011","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21614020","citation_count":23,"is_preprint":false},{"pmid":"21989738","id":"PMC_21989738","title":"CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21989738","citation_count":23,"is_preprint":false},{"pmid":"28736195","id":"PMC_28736195","title":"Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28736195","citation_count":22,"is_preprint":false},{"pmid":"14768052","id":"PMC_14768052","title":"A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14768052","citation_count":22,"is_preprint":false},{"pmid":"34303919","id":"PMC_34303919","title":"Induction of CIITA by IFN-γ in macrophages involves STAT1 activation by JAK and JNK.","date":"2021","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34303919","citation_count":22,"is_preprint":false},{"pmid":"38168631","id":"PMC_38168631","title":"LncRNA-HOXC-AS2 regulates tumor-associated macrophage polarization through the STAT1/SOCS1 and STAT1/CIITA pathways to promote the progression of non-small cell lung cancer.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38168631","citation_count":21,"is_preprint":false},{"pmid":"16730065","id":"PMC_16730065","title":"CREB and phospho-CREB interact with RFX5 and CIITA to regulate MHC class II genes.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16730065","citation_count":21,"is_preprint":false},{"pmid":"23621273","id":"PMC_23621273","title":"Exosomes from CIITA-transfected CT26 cells enhance anti- tumor effects.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23621273","citation_count":21,"is_preprint":false},{"pmid":"25765819","id":"PMC_25765819","title":"A2b adenosine signaling represses CIITA transcription via an epigenetic mechanism in vascular smooth muscle cells.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25765819","citation_count":21,"is_preprint":false},{"pmid":"17075826","id":"PMC_17075826","title":"Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/17075826","citation_count":20,"is_preprint":false},{"pmid":"26972221","id":"PMC_26972221","title":"The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26972221","citation_count":20,"is_preprint":false},{"pmid":"22513452","id":"PMC_22513452","title":"CIITA gene variants are associated with rheumatoid arthritis in Scandinavian populations.","date":"2012","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22513452","citation_count":20,"is_preprint":false},{"pmid":"19502584","id":"PMC_19502584","title":"Roles of PU.1 in monocyte- and mast cell-specific gene regulation: PU.1 transactivates CIITA pIV in cooperation with IFN-gamma.","date":"2009","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19502584","citation_count":20,"is_preprint":false},{"pmid":"16776848","id":"PMC_16776848","title":"The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients.","date":"2006","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16776848","citation_count":19,"is_preprint":false},{"pmid":"15351782","id":"PMC_15351782","title":"T cell expression of CIITA represses Th1 immunity.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15351782","citation_count":19,"is_preprint":false},{"pmid":"16920747","id":"PMC_16920747","title":"MHC2TA promoter polymorphism (-168*G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients.","date":"2006","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16920747","citation_count":19,"is_preprint":false},{"pmid":"15876426","id":"PMC_15876426","title":"Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.","date":"2005","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15876426","citation_count":19,"is_preprint":false},{"pmid":"16235089","id":"PMC_16235089","title":"Lack of MHC-II expression in activated mouse T cells correlates with DNA methylation at the CIITA-PIII region.","date":"2005","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16235089","citation_count":19,"is_preprint":false},{"pmid":"35760800","id":"PMC_35760800","title":"Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35760800","citation_count":18,"is_preprint":false},{"pmid":"19104823","id":"PMC_19104823","title":"CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.","date":"2008","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/19104823","citation_count":18,"is_preprint":false},{"pmid":"17183695","id":"PMC_17183695","title":"Polymorphism in the MHC2TA gene is associated with features of the metabolic syndrome and cardiovascular mortality.","date":"2006","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17183695","citation_count":17,"is_preprint":false},{"pmid":"11857059","id":"PMC_11857059","title":"Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).","date":"2002","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11857059","citation_count":17,"is_preprint":false},{"pmid":"24333266","id":"PMC_24333266","title":"Epigenetic modulation of RFC1, MHC2TA and HLA-DR in systemic lupus erythematosus: association with serological markers and six functional polymorphisms of one-carbon metabolic pathway.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24333266","citation_count":17,"is_preprint":false},{"pmid":"10449097","id":"PMC_10449097","title":"Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription.","date":"1999","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10449097","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50719,"output_tokens":9683,"usd":0.148701,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19658,"output_tokens":5021,"usd":0.111907,"stage2_stop_reason":"end_turn"},"total_usd":0.260608,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"CIITA expression is induced by IFN-γ, and transfection of CIITA is sufficient to activate MHC class II gene expression in class II-negative cells in the absence of IFN-γ, establishing CIITA as a general regulator of both inducible and constitutive MHC class II expression.\",\n      \"method\": \"Transfection of CIITA into class II-negative cells; IFN-γ stimulation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional reconstitution by transfection, replicated across multiple labs, foundational finding\",\n      \"pmids\": [\"8016643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CIITA mediates IFN-γ induction of HLA-DR and invariant chain (Ii) genes; a mutant cell line (G3A) selectively defective in HLA-DR and Ii induction lacks functional CIITA, and a second mutant (G1B) lacking RFX DNA-binding activity also fails to induce DRA and Ii genes by IFN-γ, linking RFX to the IFN-γ response.\",\n      \"method\": \"Analysis of IFN-γ mutant cell lines; genetic complementation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis using defined mutant cell lines, replicated across multiple independent lines\",\n      \"pmids\": [\"7600294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Both CIITA and RFX5 are essential regulators of HLA-DMA and HLA-DMB gene expression (constitutive and IFN-γ-inducible), with each cDNA able to correct the respective regulatory mutant defect.\",\n      \"method\": \"Genetic complementation of regulatory mutant cell lines by cDNA transfection\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional rescue by cDNA transfection in defined mutant lines, replicated for both CIITA and RFX5\",\n      \"pmids\": [\"7495736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The CIITA gene is controlled by multiple distinct promoters: one directing constitutive expression in dendritic cells, one in B lymphocytes, and one mediating IFN-γ-induced expression, explaining cell-type-specific and inducible MHC class II expression.\",\n      \"method\": \"Promoter-specific reporter assays; cell-type expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — promoter dissection with reporter constructs, replicated across multiple studies\",\n      \"pmids\": [\"9184229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"A dominant-negative CIITA mutant lacking the N-terminal acidic activation domain represses constitutive and IFN-γ-induced MHC class II expression of all three isotypes (HLA-DR, HLA-DQ, HLA-DP), but in a CIITA-deficient B cell line, HLA-DQ expression is not altered, revealing both CIITA-dependent and CIITA-independent class II regulatory pathways.\",\n      \"method\": \"Dominant-negative CIITA transfection; anti-CIITA monoclonal antibodies; CIITA-deficient cell lines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative approach with multiple isotypes tested, CIITA-deficient cell line control\",\n      \"pmids\": [\"9144488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RFX5 and RFXAP subunits of the RFX complex are required for both constitutive and CIITA-induced MHC class I and beta2-microglobulin transactivation, and the X1 box within the S-X-Y promoter region is critical for this regulation.\",\n      \"method\": \"Functional analysis in type III bare lymphocyte syndrome cell lines lacking RFX subunits\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined BLS patient cell lines, replicated for multiple MHC genes\",\n      \"pmids\": [\"9806639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MHC class II gene silencing in trophoblast cells is caused by inability to induce CIITA expression (not by absence of RFX/X2BP factors or IFN-γ signaling pathway defects); transfection of CIITA into trophoblast cells restores MHC class II expression.\",\n      \"method\": \"Transfection rescue assay; expression analysis of MHC class II transcription factors in trophoblast cell lines\",\n      \"journal\": \"American journal of reproductive immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional rescue by CIITA transfection, mechanism localized by exclusion of upstream pathway defects, replicated in PMID 11053628\",\n      \"pmids\": [\"9894561\", \"11053628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CIITA leucine-rich repeats (LRRs) are required for nuclear localization and in vivo recruitment to the MHC class II promoter (shown by chromatin immunoprecipitation); LRR alanine mutations abolish transactivation capacity and dominant-negative phenotype. CIITA directly interacts with RFX5, RFXANK, NF-YB, and NF-YC through LRR-independent protein-protein interactions. A novel 33 kDa protein interacts with CIITA in an LRR-sensitive manner.\",\n      \"method\": \"LRR alanine mutagenesis; chromatin immunoprecipitation; co-immunoprecipitation; nuclear localization assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis combined with ChIP and co-IP, multiple orthogonal methods in one study\",\n      \"pmids\": [\"11003667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Lack of CIITA expression in trophoblast cells is due to hypermethylation of the IFN-γ-inducible promoter IV (PIV) of CIITA; introduction of exogenous CIITA induces MHC class I and II surface expression and antigen presentation capacity.\",\n      \"method\": \"Bisulfite methylation analysis of CIITA PIV; CIITA transfection rescue; antigen presentation assay\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — bisulfite sequencing plus functional rescue, two orthogonal methods\",\n      \"pmids\": [\"11053628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CIITA forms homomeric complexes with itself through a central region including the GTP-binding domain; LXXLL motifs in the GTP-binding domain are essential for self-association. The central region also interacts with the C-terminal LRR and N-terminal acidic domain. CIITA mutants differ in activation function, subcellular localization, and dominant-negative potential.\",\n      \"method\": \"Co-immunoprecipitation; deletion/point mutagenesis; subcellular localization assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with mutagenesis, single lab, multiple constructs\",\n      \"pmids\": [\"11438649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-γ induction of CIITA from promoter IV (PIV) requires sequential binding of STAT1 (within 30 min, accompanied by modest histone H3/H4 acetylation) followed by IRF-1 synthesis and binding (>120 min) before CIITA mRNA is detected. Fetal trophoblast-like cells refractory to CIITA induction fail to assemble these factors; bisulfite sequencing shows strong PIV hypermethylation in these cells.\",\n      \"method\": \"Chromatin immunoprecipitation kinetics; bisulfite sequencing; IFN-γ stimulation time course\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP kinetics combined with bisulfite sequencing, two orthogonal methods, clear temporal resolution\",\n      \"pmids\": [\"12052885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BRG1, the ATPase subunit of the SWI/SNF chromatin-remodeling complex, is required for IFN-γ induction of CIITA; reconstitution with BRG1 but not an ATPase-deficient mutant (K798R) rescues CIITA induction. BRG1 interacts directly with the endogenous CIITA promoter in an IFN-γ-inducible fashion, and its activity is required for chromatin remodeling at the CIITA locus.\",\n      \"method\": \"BRG1/hBRM-deficient cell lines; BRG1 reconstitution; chromatin immunoprecipitation; DNase I footprinting; restriction enzyme accessibility\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — functional reconstitution with ATPase-dead mutant control, ChIP, and in vivo chromatin accessibility, multiple orthogonal methods\",\n      \"pmids\": [\"11953317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CIITA regulates MHC class II transcription initiation by recruiting CDK7 and CDK9 kinases and enhancing CDK7-mediated phosphorylation of RNA Pol II at Ser5, promoting promoter clearance. CIITA is recruited to the DRA enhanceosome after IFN-γ, leading to recruitment of CBP and GCN5 coactivators, histone acetylation, and SWI/SNF recruitment.\",\n      \"method\": \"Chromatin immunoprecipitation temporal analysis; kinase activity assays; IFN-γ stimulation time course\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP temporal dissection, kinase recruitment assays, multiple orthogonal methods\",\n      \"pmids\": [\"14517250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The enhanceosome (RFX complex) and CIITA make variable, promoter-dependent contributions to histone acetylation and recruitment of TBP, TFIIB, and RNA Pol II; CIITA is generally required at multiple levels of the activation process across four co-regulated MHC class II genes.\",\n      \"method\": \"Chromatin immunoprecipitation in RFX-deficient and CIITA-deficient cell lines; analysis of four MHC-II promoters\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP in defined mutant cell lines, multiple genes compared, two loss-of-function backgrounds\",\n      \"pmids\": [\"11889043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CIITA activates expression of the semaphorin receptor plexin-A1 in dendritic cells; plexin-A1 is required for T cell stimulation by antigen-pulsed DCs but not for peptide binding to MHC. This was identified by cDNA microarray in CIITA-deficient mice and confirmed by shRNA knockdown.\",\n      \"method\": \"cDNA microarray; shRNA knockdown; T cell stimulation assays; CIITA-deficient and MHC class II-deficient mouse DCs\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — microarray plus shRNA functional validation, CIITA-deficient mouse model, antigen presentation readout\",\n      \"pmids\": [\"12910265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CIITA contains acetyltransferase (AT) and kinase activities that contribute to MHC class I and II gene transcription; as a general transcription factor, CIITA can functionally replace the TFIID component TAF1 with parallel substrate specificity and regulatory features.\",\n      \"method\": \"Biochemical activity assays; functional complementation; mutagenesis (reviewed with experimental support cited within)\",\n      \"journal\": \"Frontiers in immunology (review of experimental findings)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — review citing in vitro assay data for AT and kinase activities, but primary evidence not directly in this abstract\",\n      \"pmids\": [\"24391648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Phosphorylation of CIITA at serine residues 286, 288, and 293 downregulates CIITA activity; the nuclear form of CIITA is predominantly phosphorylated whereas cytoplasmic CIITA is predominantly unphosphorylated. Double mutations at these sites increase nuclear CIITA and enhance endogenous MHC class II expression.\",\n      \"method\": \"Serine-to-alanine mutagenesis; subcellular fractionation; endogenous MHC class II expression assays; phosphorylation site mapping\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis combined with fractionation and functional assay, single lab\",\n      \"pmids\": [\"15210796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RFX and CIITA bind to novel distal S'-Y' modules located far from known MHC-II gene promoters; these elements function as transcriptional enhancers that are bona fide targets of RFX and CIITA in B cells and IFN-γ-induced cells, inducing broad domains of histone hyperacetylation.\",\n      \"method\": \"Computational S-Y motif identification; chromatin immunoprecipitation; reporter assays; histone acetylation ChIP\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay combined, computational discovery followed by functional validation\",\n      \"pmids\": [\"15528357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-γ-induced CIITA expression by TLR2-induced MAPK (p38 and ERK) signaling, which causes histone hypoacetylation at CIITA promoter IV and suppression of BRG1 recruitment; this effect is absent in TLR2-deficient macrophages.\",\n      \"method\": \"Chromatin immunoprecipitation; TLR2 knockout macrophages; MAPK inhibitors (p38, ERK); histone acetylation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with TLR2-KO genetic control and pharmacological inhibitors, multiple orthogonal approaches\",\n      \"pmids\": [\"16547269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"EZH2, a component of Polycomb repressive complex 2, is present at CIITA promoter IV chromatin in uveal melanoma cells and is associated with trimethylation of H3K27; RNAi-mediated knockdown of EZH2 increases IFN-γ-inducible CIITA transcript levels.\",\n      \"method\": \"Chromatin immunoprecipitation; RNAi knockdown; histone methylation analysis (3Me-K27-H3)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus RNAi functional validation, single lab\",\n      \"pmids\": [\"17911618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"M. tuberculosis 19-kDa lipoprotein induces C/EBPβ and C/EBPδ binding to CIITA promoters I and IV, correlating with inhibition of IFN-γ-induced CIITA expression; constitutive expression of C/EBPβ LIP isoform inhibits IFN-γ-induced CIITA expression.\",\n      \"method\": \"Chromatin immunoprecipitation; oligodeoxynucleotide pulldown; transfection of C/EBPβ LIP; quantitative RT-PCR\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP combined with functional transfection assay, single lab\",\n      \"pmids\": [\"17982082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ZXDC, a novel zinc finger protein, interacts with the LRR-containing region of CIITA; overexpression of ZXDC super-activates MHC class I and class II promoters by CIITA, and ZXDC silencing reduces CIITA-dependent MHC class II transcription.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation; overexpression and shRNA knockdown reporter assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus co-IP binding, functional reporter assay, single lab\",\n      \"pmids\": [\"16600381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZXDA and ZXDC form a heterocomplex (as well as homodimers) through their zinc finger-containing regions; the ZXDA-ZXDC complex interacts with CIITA and is important for MHC class II gene transcription; ZXDC is present at MHC class II promoters before and after IFN-γ treatment.\",\n      \"method\": \"Co-immunoprecipitation; knockdown and overexpression assays; chromatin immunoprecipitation\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP binding plus ChIP promoter occupancy, single lab, two orthogonal methods\",\n      \"pmids\": [\"17493635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRG1 regulates IFN-γ-mediated CIITA induction through many interdependent distal enhancers rather than through the promoter alone; at uninduced CIITA, BRG1-independent chromatin loops pre-exist, and IFN-γ-induced recruitment of STAT1, IRF1, p300, and histone modifications at distal elements all show BRG1 dependency.\",\n      \"method\": \"Chromatin immunoprecipitation; chromosome conformation capture (3C); BRG1-deficient cells; histone modification analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP combined with 3C chromatin looping and BRG1-deficient functional analysis, multiple orthogonal methods\",\n      \"pmids\": [\"18500344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PU.1 binds a distal regulatory element (HSS1, 11 kb upstream of CIITA pIII) required for B cell-specific CIITA expression; chromatin conformation capture shows HSS1 physically interacts with CIITA pIII in B cells through PU.1-mediated chromatin looping; PU.1 depletion reduces CIITA expression.\",\n      \"method\": \"DNase I hypersensitivity; chromatin immunoprecipitation; chromatin conformation capture (3C); shRNA knockdown; bacterial artificial chromosome reporter assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, 3C, functional deletion, and shRNA, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"20363966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CIITA inhibits HTLV-1 replication by physically interacting with the viral transactivator Tax-1 (via CIITA residues 1-252 and 253-410 interacting with Tax-1 residues 1-108); only CIITA residues 1-252 mediate Tax-1 inhibition. CIITA impairs the physical and functional interaction of Tax-1 with cellular coactivators PCAF, CREB, and ATF1, required for optimal HTLV-1 LTR activation.\",\n      \"method\": \"Co-immunoprecipitation in vivo; deletion mutagenesis; HTLV-1 LTR luciferase reporter assay; coactivator overexpression rescue\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with deletion mapping, functional reporter assay, rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"21813598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CIITA negatively regulates IL-10 expression in dendritic cells; CIITA-deficient DCs produce increased IL-10 mRNA and protein, while reintroduction of CIITA into CIITA-/- DCs reduces IL-10 production; co-transfection of CIITA with an IL-10 promoter-reporter decreases IL-10 promoter activity.\",\n      \"method\": \"CIITA-/- mouse DCs; CIITA reconstitution; IL-10 promoter-reporter assay; LPS/CpG stimulation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse plus reconstitution plus reporter assay, single lab\",\n      \"pmids\": [\"15661876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PRDM1/Blimp-1 silences CIITA expression in maturing dendritic cells by recruiting co-repressors G9a and HDAC2 to CIITA promoter I, causing loss of histone acetylation and acquisition of H3K9 dimethylation and HP1γ; IRF8/PU.1 heterodimer binding is required for CIITApI activation in immature DCs and is blocked by PRDM1.\",\n      \"method\": \"In vivo genomic footprinting; chromatin immunoprecipitation; IRF8-null mouse DCs; PRDM1 reporter assays; DC maturation model\",\n      \"journal\": \"Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP combined with IRF8-null mice, in vivo footprinting, and functional reporter assays, multiple orthogonal methods\",\n      \"pmids\": [\"21216962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SIRT1 deacetylase interacts with and deacetylates CIITA; SIRT1 activation augments MHC II transcription by protecting CIITA from proteasomal degradation and promoting nuclear accumulation and promoter binding; SIRT1 depletion increases CIITA acetylation and attenuates its activity. Stress stimuli (hypobaric hypoxia, oxLDL) induce CIITA acetylation and suppress its activity by inhibiting SIRT1.\",\n      \"method\": \"Co-immunoprecipitation; deacetylation assay; proteasome inhibition; nuclear fractionation; chromatin immunoprecipitation; SIRT1 activator/inhibitor treatment\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, proteasome assay, ChIP, and stress stimuli models, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"21890893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Genome-wide ChIP-seq reveals CIITA binds 480 sites in B cells, predominantly at active promoters and enhancers containing accessible chromatin; CIITA binding correlates with increased H3K27 acetylation at non-regulated loci, suggesting a chromatin-poising function; computational modeling of XY box motifs defines sequence constraints distinguishing CIITA-mediated regulation from mere binding.\",\n      \"method\": \"ChIP-seq; CIITA-null cell lines (including CRISPR/Cas9-generated); histone modification analysis; computational motif modeling\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — genome-wide ChIP-seq with CRISPR KO validation, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"25753668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CIITA inhibits HIV-1 replication in myeloid (U937) cells by targeting the viral transactivator Tat to inhibit Tat-dependent HIV-1 LTR transactivation; this is independent of TRIM22 expression. Overexpression of CIITA in permissive U937 Plus cells restores suppression of Tat transactivation.\",\n      \"method\": \"Stable CIITA overexpression; HIV-1 LTR luciferase reporter assay; reverse transcriptase activity measurement; flow cytometry; western blot\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assay and viral replication measurement with gain-of-function, single lab\",\n      \"pmids\": [\"27089879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRMT1 methylates CIITA and promotes CIITA proteasomal degradation, thereby repressing MHC class II transcription in macrophages; IFN-γ treatment downregulates PRMT1 expression and attenuates PRMT1 binding to the MHC II promoter; PRMT1 overexpression represses while PRMT1 depletion enhances MHC II transactivation.\",\n      \"method\": \"Co-immunoprecipitation; in vitro methylation assay; chromatin immunoprecipitation; PRMT1 overexpression and knockdown; MHC II promoter reporter assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus in vitro methylation, ChIP, and gain/loss-of-function, single lab\",\n      \"pmids\": [\"28094290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PRMT5 interacts with CIITA and is recruited by CIITA to the MHC II promoter; PRMT5 potentiates IFN-γ-induced MHC II transcription in an enzyme activity-dependent manner by symmetrically dimethylating H3R2 (H3R2Me2s) and mediating synergy between PRMT5 and ASH2/WDR5; PRMT5 silencing or inhibition suppresses MHC II transactivation.\",\n      \"method\": \"Co-immunoprecipitation; chromatin immunoprecipitation; PRMT5 overexpression and knockdown; enzyme activity inhibitor (MTA); histone methylation assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ChIP, and gain/loss-of-function with enzyme-dead validation, single lab\",\n      \"pmids\": [\"26972221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NFAT5 is required for expression of CIITA and MHC class II in macrophages (but not dendritic cells); NFAT5-deficient macrophages show defective CD4+ T cell activation and impaired graft rejection in vivo. NFAT5 regulates a distal upstream enhancer of Ciita that physically interacts with the Ciita myeloid promoter I and exhibits NFAT5-dependent H3K27 acetylation.\",\n      \"method\": \"NFAT5-deficient macrophages; CHIP-seq (ultrasequencing of NFAT5-immunoprecipitated chromatin); H3K27 acetylation ChIP; in vivo graft rejection model; CD4+ T cell activation assay\",\n      \"journal\": \"Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq combined with KO mouse functional assays (T cell activation, graft rejection), multiple orthogonal methods\",\n      \"pmids\": [\"30327417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CIITA interacts with and recruits the histone H3K9 trimethyltransferase SUV39H1 to the eNOS promoter, resulting in H3K9Me3 enrichment and transcriptional repression of eNOS in endothelial cells in response to IFN-γ; CIITA depletion normalizes H3K4Me3 and H3K9Me3 at the eNOS promoter; SUV39H1 silencing abrogates IFN-γ-induced eNOS repression.\",\n      \"method\": \"Chromatin immunoprecipitation; co-immunoprecipitation; CIITA overexpression and knockdown; SUV39H1 knockdown; histone methylation analysis (H3K9Me3, H3K4Me3)\",\n      \"journal\": \"Biochimica et biophysica acta. Gene regulatory mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP combined with co-IP and gain/loss-of-function, single lab\",\n      \"pmids\": [\"30716531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CIITA induces resistance to Ebola virus by activating expression of the p41 isoform of the invariant chain CD74, which inhibits viral entry by blocking cathepsin-mediated processing of the Ebola glycoprotein; CD74 p41 also blocks the endosomal entry pathway of SARS-CoV-2 and other coronaviruses.\",\n      \"method\": \"Transposon-mediated gene-activation screen; CD74 p41 expression; viral entry assays; cathepsin activity assays; CIITA and CD74 gain-of-function\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional screen followed by mechanistic validation of CD74 p41 as effector, viral entry and cathepsin assays, multiple viruses tested\",\n      \"pmids\": [\"32855215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FBXO11, a member of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex, is a binding partner and E3 ligase for CIITA; FBXO11 promotes ubiquitin-dependent proteasomal degradation of CIITA and is the major regulator of CIITA half-life. FBXO11 expression reduces MHC class II promoter activity, transcript levels, and surface expression through CIITA downregulation; FBXO11-deficient cells display increased MHC II and related genes.\",\n      \"method\": \"Unbiased proteomics for CIITA-binding proteins; cycloheximide chase assay; ubiquitination assay; MHC II promoter reporter; flow cytometry; FBXO11-deficient human and mouse cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — unbiased proteomics plus degradation assay, ubiquitination assay, and KO cell functional validation, multiple orthogonal methods\",\n      \"pmids\": [\"37279268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In osteocytes, CIITA upregulates secretion of osteolytic cytokines (RANKL/TNFSF11 and sclerostin/SOST) through histone H3K14 acetylation at their promoters, promoting osteoclastogenesis and decreasing osteoblastogenesis; myeloma cell-secreted 2-deoxy-D-ribose upregulates CIITA expression in osteocytes through STAT1/IRF1 signaling.\",\n      \"method\": \"Chromatin immunoprecipitation (H3K14 acetylation); CIITA overexpression in osteocytes; osteoclastogenesis assays; STAT1/IRF1 pathway analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus gain-of-function and pathway inhibition, single lab\",\n      \"pmids\": [\"35760800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CREB and phospho-CREB interact with CIITA and with the RFX5 subunit of the RFX complex through the C-terminal portion of CREB; phospho-CREB is found at the HLA-DRA promoter by ChIP; phosphorylation of CREB enhances but is not required for transcription from MHC-II promoter reporters.\",\n      \"method\": \"Co-immunoprecipitation with CREB mutants; reporter assays; chromatin immunoprecipitation\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with mutant mapping, ChIP, and reporter assay, single lab\",\n      \"pmids\": [\"16730065\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CIITA is a master transcriptional coactivator that does not bind DNA directly but is recruited to MHC class II (and related) promoters through protein–protein interactions with the RFX complex (RFX5, RFXANK), NF-Y, and CREB; once at the promoter, CIITA coordinates chromatin remodeling (via BRG1/SWI/SNF), histone acetylation (recruiting CBP/GCN5/PCAF and possessing intrinsic acetyltransferase activity), and transcription initiation (via CDK7/CDK9-mediated Ser5 phosphorylation of RNA Pol II). Its nuclear localization depends on intact leucine-rich repeats (LRRs), and its activity is tightly regulated by post-translational modifications including phosphorylation (at Ser286/288/293 to downregulate activity), acetylation (reversed by SIRT1 to promote stability and nuclear accumulation), methylation by PRMT1 (promoting proteasomal degradation), and ubiquitin-dependent proteasomal degradation driven by the E3 ligase FBXO11. CIITA expression is itself governed by multiple cell-type-specific promoters controlled by STAT1, IRF-1, PU.1/IRF8, NFAT5, and epigenetic mechanisms including DNA methylation and histone modifications; it also functions as a viral restriction factor by sequestering Tax-1 (HTLV-1) and Tat (HIV-1) transactivators and by inducing CD74 p41 to block cathepsin-mediated entry of Ebola virus and SARS-CoV-2.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CIITA is the master transcriptional coactivator of the MHC class II response, sufficient to switch on MHC class II genes in class II-negative cells and acting as the general regulator of both constitutive and IFN-\\u03b3-inducible class II expression [#0, #1]. It does not bind DNA itself but is recruited to the conserved S-X-Y promoter module through the RFX complex (RFX5, RFXANK), NF-Y (NF-YB/NF-YC), and CREB, with these LRR-independent protein-protein contacts positioning CIITA at the enhanceosome while its leucine-rich repeats govern nuclear localization and stable promoter occupancy [#7, #5, #38]. Once recruited, CIITA orchestrates a coordinated activation program: it directs SWI/SNF-dependent chromatin remodeling via the BRG1 ATPase, recruits the CBP/GCN5 acetyltransferases to drive histone acetylation, and promotes transcription initiation by recruiting CDK7/CDK9 and enhancing Ser5 phosphorylation of RNA Pol II for promoter clearance [#11, #12, #13]. Genome-wide it binds hundreds of active promoters and enhancers, including distal S'-Y' modules, where it poises chromatin through H3K27 acetylation [#29, #17]. CIITA expression is itself the principal control point, set by multiple cell-type-specific promoters whose use depends on STAT1/IRF-1 (IFN-\\u03b3-inducible promoter IV), PU.1/IRF8 (B-cell and DC promoters), and NFAT5 (myeloid), and is silenced by promoter hypermethylation, EZH2/H3K27me3, and PRDM1-recruited G9a/HDAC2 repression [#3, #10, #24, #33, #8, #19, #27]. CIITA activity and stability are tuned by post-translational modifications\\u2014inhibitory phosphorylation at Ser286/288/293, SIRT1-reversible acetylation controlling nuclear accumulation, PRMT1 methylation driving degradation, and FBXO11-mediated ubiquitin-dependent proteasomal turnover as the major determinant of its half-life [#16, #28, #31, #36]. Beyond antigen presentation CIITA acts as a viral restriction factor, sequestering the HTLV-1 Tax-1 and HIV-1 Tat transactivators and inducing the CD74 p41 isoform to block cathepsin-dependent entry of Ebola virus and SARS-CoV-2, and it can also act as a context-dependent repressor, recruiting SUV39H1 to silence eNOS and suppressing IL-10 [#25, #30, #35, #34, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that a single factor controls the MHC class II regulon, answering whether class II induction by IFN-\\u03b3 required a dedicated master regulator.\",\n      \"evidence\": \"Transfection of CIITA into class II-negative cells and IFN-\\u03b3 stimulation, plus genetic complementation of IFN-\\u03b3-defective mutant cell lines\",\n      \"pmids\": [\"8016643\", \"7600294\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how CIITA reaches the promoter\", \"Mechanism of transactivation unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the partition of labor between CIITA and the RFX complex, showing both are essential and act on overlapping sets of MHC genes including HLA-DM.\",\n      \"evidence\": \"cDNA complementation of distinct regulatory mutant cell lines for HLA-DMA/DMB\",\n      \"pmids\": [\"7495736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physical relationship between CIITA and RFX not yet shown\", \"Promoter element requirements undefined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Explained cell-type-specific and inducible class II expression by mapping CIITA to multiple distinct promoters and identifying CIITA-independent regulatory routes.\",\n      \"evidence\": \"Promoter-specific reporter assays, cell-type expression analysis, and dominant-negative CIITA lacking the activation domain\",\n      \"pmids\": [\"9184229\", \"9144488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream transcription factors at each promoter not identified\", \"Basis of CIITA-independent HLA-DQ regulation unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed CIITA also governs MHC class I and beta2-microglobulin via the RFX/S-X-Y machinery, and that physiological class II silencing in trophoblast reflects failure to induce CIITA itself.\",\n      \"evidence\": \"Bare lymphocyte syndrome cell lines lacking RFX5/RFXAP; transfection rescue and exclusion of upstream defects in trophoblast\",\n      \"pmids\": [\"9806639\", \"9894561\", \"11053628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cause of CIITA promoter silencing in trophoblast not yet defined\", \"Direct CIITA-RFX contact still inferred\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Mapped the structural basis of CIITA recruitment and assembly, distinguishing LRR-dependent localization/promoter binding from LRR-independent partner contacts and self-association.\",\n      \"evidence\": \"LRR alanine mutagenesis, ChIP, co-IP with RFX5/RFXANK/NF-YB/NF-YC, nuclear localization assays, and homodimerization mapping; bisulfite analysis of promoter IV in trophoblast\",\n      \"pmids\": [\"11003667\", \"11438649\", \"11053628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the LRR-sensitive 33 kDa partner unresolved\", \"Functional role of GTP-binding domain self-association unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved both how CIITA is induced and what it does at target promoters, defining the STAT1\\u2192IRF-1 kinetic cascade, BRG1/SWI/SNF chromatin remodeling, and CDK7/CDK9-mediated Pol II Ser5 phosphorylation.\",\n      \"evidence\": \"ChIP kinetics with bisulfite sequencing, BRG1 reconstitution with ATPase-dead control, kinase recruitment assays, and ChIP across four MHC-II promoters\",\n      \"pmids\": [\"12052885\", \"11953317\", \"14517250\", \"11889043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CIITA enzymatic activities are intrinsic vs recruited not settled\", \"Quantitative contributions of each step vary by promoter\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Extended the CIITA regulon beyond MHC to identify functional non-MHC targets relevant to antigen presentation, such as plexin-A1 in dendritic cells.\",\n      \"evidence\": \"cDNA microarray in CIITA-deficient mouse DCs with shRNA validation and T-cell stimulation assays\",\n      \"pmids\": [\"12910265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter elements mediating CIITA control of plexin-A1 undefined\", \"Breadth of non-MHC targets not yet genome-wide\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Proposed CIITA as a general transcription factor with intrinsic acetyltransferase/kinase activities and TAF1-like function, and uncovered distal S'-Y' enhancers and inhibitory phosphorylation as activity controls.\",\n      \"evidence\": \"Biochemical activity assays and TAF1 complementation (reviewed); ChIP/reporter of distal enhancers; Ser286/288/293 mutagenesis with fractionation\",\n      \"pmids\": [\"24391648\", \"15528357\", \"15210796\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Primary structural/biochemical evidence for intrinsic enzymatic activities limited\", \"Kinase responsible for inhibitory Ser phosphorylation not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined transcriptional repression of CIITA by pathogens and the cofactor environment, linking TLR2/MAPK signaling, C/EBP, EZH2, ZXDC/ZXDA, and CREB to CIITA promoter control and coactivation.\",\n      \"evidence\": \"ChIP with TLR2-KO macrophages and MAPK inhibitors; C/EBP\\u03b2 LIP transfection; EZH2 RNAi; yeast two-hybrid and co-IP for ZXDC/ZXDA; CREB mutant co-IP and ChIP\",\n      \"pmids\": [\"16547269\", \"17982082\", \"17911618\", \"16600381\", \"16730065\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic interplay among these repressors not integrated\", \"Direct vs indirect cofactor effects on CIITA not all resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed that CIITA induction is controlled through long-range chromatin architecture, with BRG1-dependent distal enhancers and pre-existing chromatin loops.\",\n      \"evidence\": \"ChIP combined with chromosome conformation capture (3C) in BRG1-deficient cells with histone modification analysis\",\n      \"pmids\": [\"18500344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Architectural proteins establishing the loops not identified\", \"Mechanism of BRG1-independent pre-existing loops unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified lineage- and maturation-specific control of CIITA and the post-translational acetylation switch, and uncovered CIITA's antiviral and immunoregulatory moonlighting functions.\",\n      \"evidence\": \"PU.1/HSS1 3C and shRNA; PRDM1/G9a/HDAC2 footprinting in IRF8-null DCs; SIRT1 deacetylation/proteasome/ChIP assays; Tax-1 co-IP and LTR reporter; CIITA-/- DC IL-10 reporter\",\n      \"pmids\": [\"20363966\", \"21216962\", \"21890893\", \"21813598\", \"15661876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DC maturation triggers PRDM1 recruitment unresolved\", \"Specificity determinants of CIITA acetylation sites not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established arginine methylation as a bidirectional regulator of CIITA, with PRMT1 driving degradation and PRMT5 potentiating transcription, and defined the genome-wide CIITA binding landscape.\",\n      \"evidence\": \"Co-IP and in vitro methylation with PRMT1/PRMT5 gain/loss-of-function and ChIP; genome-wide ChIP-seq with CRISPR-null validation\",\n      \"pmids\": [\"28094290\", \"26972221\", \"25753668\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methylated residues on CIITA not precisely mapped\", \"Distinction between CIITA binding and functional regulation incompletely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined NFAT5-dependent myeloid CIITA control, the FBXO11 E3 ligase as the major determinant of CIITA half-life, and effector mechanisms of CIITA in viral restriction, vascular gene silencing, and bone remodeling.\",\n      \"evidence\": \"NFAT5-KO macrophage ChIP-seq with graft rejection; FBXO11 proteomics, ubiquitination and cycloheximide chase; CD74 p41 viral entry/cathepsin assays; SUV39H1 co-IP/ChIP at eNOS; H3K14ac ChIP in osteocytes; HIV-1 Tat LTR reporter\",\n      \"pmids\": [\"30327417\", \"37279268\", \"32855215\", \"30716531\", \"35760800\", \"27089879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals selecting CIITA for FBXO11 ubiquitination not defined\", \"Mechanism by which CIITA switches between activator and SUV39H1-recruiting repressor unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse post-translational modifications (phosphorylation, acetylation, arginine methylation, ubiquitination) are integrated to set CIITA activity, stability, and its choice between activator and repressor roles remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking PTM crosstalk to functional output\", \"Structural basis of CIITA assembly at the enhanceosome not determined\", \"Determinants of activator vs repressor mode unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 7, 29]},\n      {\"term_id\": \"GO:0140223\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 15]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [25, 30, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 14, 35]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 11, 12, 13]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [11, 23, 27, 34]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [25, 30, 35]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RFX5\", \"RFXANK\", \"NFYB\", \"NFYC\", \"CREB\", \"ZXDC\", \"SIRT1\", \"FBXO11\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}